For the quarter ended June 2023, Sotera Health Company (SHC - Free Report) reported revenue of $255.28 million, down 4.3% over the same period last year. EPS came in at $0.21, compared to $0.27 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $261.05 million, representing a surprise of -2.21%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.18.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sotera Health Company performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenues- Sterigenics: $166.59 million versus the two-analyst average estimate of $169.63 million. The reported number represents a year-over-year change of +5.6%.
- Net Revenues- Nelson Labs: $56.72 million versus $57.21 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.8% change.
- Net Revenues- Nordion: $31.98 million versus $35.33 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -36.7% change.
- Segment Income- Sterigenics: $91.45 million versus $90.94 million estimated by two analysts on average.
- Segment Income- Nelson Labs: $19.25 million compared to the $19.19 million average estimate based on two analysts.
- Segment Income- Nordion: $17.78 million versus $17.82 million estimated by two analysts on average.
View all Key Company Metrics for Sotera Health Company here>>>Shares of Sotera Health Company have returned +1% over the past month versus the Zacks S&P 500 composite's +1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
For the quarter ended June 2023, Sotera Health Company (SHC - Free Report) reported revenue of $255.28 million, down 4.3% over the same period last year. EPS came in at $0.21, compared to $0.27 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $261.05 million, representing a surprise of -2.21%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.18.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sotera Health Company performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenues- Sterigenics: $166.59 million versus the two-analyst average estimate of $169.63 million. The reported number represents a year-over-year change of +5.6%.
- Net Revenues- Nelson Labs: $56.72 million versus $57.21 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.8% change.
- Net Revenues- Nordion: $31.98 million versus $35.33 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -36.7% change.
- Segment Income- Sterigenics: $91.45 million versus $90.94 million estimated by two analysts on average.
- Segment Income- Nelson Labs: $19.25 million compared to the $19.19 million average estimate based on two analysts.
- Segment Income- Nordion: $17.78 million versus $17.82 million estimated by two analysts on average.
View all Key Company Metrics for Sotera Health Company here>>>Shares of Sotera Health Company have returned +1% over the past month versus the Zacks S&P 500 composite's +1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on SHC - FREE